RAP-219 for Bipolar I Disorder
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 250 (estimated)
- Sponsor
- Rapport Therapeutics Inc. · Industry
This trial is looking for adults with bipolar I disorder who have experienced at least one manic episode. Participants will take an investigational drug called RAP-219 to help assess its safety and effectiveness.
You may be able to join if
- I have been diagnosed with bipolar I disorder.
- I have had at least one manic episode that needed treatment in the past 5 years.
You may not be able to join if
- I have schizophrenia or schizoaffective disorder.
- I have a major depressive disorder.
- I have a severe alcohol use disorder.
- I have cognitive disorders like dementia.
- I have borderline personality disorder.
- I have experienced 4 or more mood episodes in the past year.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThis is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted to determine if RAP-219 is safe and effective in participants experiencing mania associated with bipolar I disorder.
Loading trial locations…